FindTrial
Sign In

IMMUNOHISTOCHEMICAL EXPRESSION OF PDL1 IN SEROUS CARCINOMA OVARY

ROLE OF PDL1 IN SEROUS CARCINOMA OVARY AND ITS ASSOCIATION WITH TUMOUR INFILTRATING LYMPHOCYTES (TILs)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/07/034814
Enrollment
30
Registered
2021-07-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C569- Malignant neoplasm of unspecifiedovary

Interventions

None listed

Sponsors

Dr Anubhuti Chaturvedi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Cases diagnosed as Serous Ovarian Cancer on Histopathology

Exclusion criteria

Exclusion criteria: •Other Histological types of Epithelial Ovarian Carcinomas- Endometrioid, Clear cell, and Mucinous type •Other types of Ovarian Carcinomas- Germ Cell, Sex cord-Stromal

Design outcomes

Primary

MeasureTime frame
Primary Outcome: To assess the immunohistochemical expression of PDL1 marker in Serous Carcinoma of the Ovary. Timepoint: 1 year—

Secondary

MeasureTime frame
Secondary Outcome: To study the association of PDL1 expression with Tumor Infiltrating Lymphocytes (TILs) in Serous Carcinoma of the Ovary. Timepoint: 1 year—

Countries

India

Contacts

Public ContactDr Reena Tomar

Maulana Azad Medical College

drreenat@yahoo.com9711972630

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026